LS CancerDiag Ltd is committed to reducing cancer mortality rates with a simple and accurate diagnostic method that detects Lynch syndrome, the world’s most common inherited cancer predisposition, even before tumors develop. Our vision is to see DiagMMR® as a new global testing standard in Lynch syndrome diagnostics.
Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With around 1 in 300 people of the world’s population carrying the Lynch syndrome mutation, there are millions of people under a severe risk for being affected by Lynch syndrome.
Our groundbreaking DiagMMR® assay is an unique functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC).
Our mission is to confirm or exclude Lynch syndrome, provide actionable results and help prevent cancer through an innovation that dramatically simplify diagnostics of Lynch syndrome by delivering predictive, reliable and accurate results.
Lynch syndrome is characterized by an inherited functional deficiency in a mismatch repair (MMR) proteins. The genes encoding for MMR proteins have been identified and studied for many years. Our founder and CEO Prof. Minna Nyström is an internationally distinguished expert in that field and back in the 90s, when she started to use sequencing as a novel method to enable disease causing mutation finding in the susceptibility genes, she already saw possible limitations in the method.
She realized that knowing the DNA sequence change, while being useful information, would not reveal the actual malfunction of the encoded MMR proteins, unless it was possible to test for exactly that. So she set out to develop such a method. DiagMMR® is the result of many years of dedicated research to get to the point, where MMR functionality, and functional deficiency typical to Lynch syndrome, can be analyzed directly without the need of any underlying clinical data. It can therefore help medical professionals and patients alike, by providing actionable results and help answering questions that remained unanswered to this day.
This new method supports the trend and the need to combine existing data with new insights and data points to enable more personalized treatments and preventive measures in the fight against cancer.
2013
Founding year
LS CancerDiag is founded as a spin-off from the University of Helsinki, also thanks to an ERC grant.
2015
First patent granted in Australia
Australia is the first country to grant the patent to LS CancerDiag for the DiagMMR® innovation.
2016
The clinical study to validate DiagMMR® is initiated with the central hopsitals of Helsinki and Jyväskylä.
2018
The extensive clinical validation is complete with excellent accuracy results.
2019
CE mark as IVD MD obtained
DiagMMR® is CE marked as in vitro diagnostics medical device.
2019
DiagMMR® is launched in the Finnish market in collaboration with two distribution partners.
2020
LS CancerDiag is selected for various programmes across Europe for supporting the new phase of growth.
This document informs you about privacy issues such as the collection, storage, use and disclosure of personal information received from users of this Website, and of personal information received in the course of the provided services.
The LS CancerDiag Ltd is controller of your personal data, which it collects from its website visitors. This means that LS CancerDiag:
Related to its services, LS CancerDiag is processor of your personal data, which it receives from the controller, for example, your hospital. Regarding this data, LS CancerDiag is processor of your data, which means that we:
If you have any questions about this Privacy Policy, your data, or if you would like to exercise one of your data protection rights, please do not hesitate to contact our data protection officer at:
LS CancerDiag Ltd
Business ID 2558287-9
c/o Terkko Health Hub
Haartmaninkatu 4, Building 14
00290 Helsinki
Finland
From our website visitors, we collect data such as:
We collect this data based on your consent, Article 6 (1) (a) of the European General Data Protection Regulation 2016/679, because you like to stay updated on our newsletters, marketing offers, or you have reached out to us for information or questions.
Regarding our services LS CancerDiag collects data such as:
This data is collected to fulfill on the contractual obligation, pursuant Article 6 (1) (b) of the European General Data Protection Regulation 2016/679.
Since LS CancerDiag is collecting special category data, such as genetic data and health-related data, we have ensured additional organizational measures, such as an appointed data protection officer, and implemented technical measures to secure the data and ensure safe processing.
Research data
We use health-related and genetic data, we receive according to contractual obligations, in encrypted form to research and improve analysis and diagnoses related to Lynch syndrome.
Analytical data
Analytical data is anonymously collected and therefore not subjected to the GDPR.
The Company stores your data in secure locations, such as the password protected and authorization-accessible database of the host domain of the Company.
With regards to European data protection legislation and Finnish taxation laws, we will store your data that is necessary for tax-related purposes for a minimum of 6 years.
Data related to your health, and results from the research projects, will be stored for as long as the project aim last.
Once your personal data is removed based on one of the reasons as stated above, it cannot be retrieved unless you or the contractual provider sends it again to us for reasons as stated previously in this policy.
We do not internationally transfer your data outside the Union, or share it to Third Parties for marketing purposes.
We do not use any automated individual decision-making tools.
You, a website visitor, customer or other party, have at all times the right to:
This policy was last updated December 2020. LS CancerDiag Ltd will keep this privacy policy continuously under review and reserves the right to modify this document. LS CancerDiag Ltd
advises you to regularly consult this document for the latest updates.
Should you wish to report a complaint or you feel LS CancerDiag Ltd has not addressed your concerns in a satisfying manner, you may contact the Data Protection Authority in Finland or in your country of residence.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.